Drugs / BT-001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07687875 | Jun 2026 → Dec 2028 expected | rectal cancer | Henry Smith | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04725331 | Feb 2021 → Oct 2025 | cutaneous neuroendocrine carcinoma, melanoma, metastatic malignant neoplasm, non-small cell lung carcinoma +2 | Transgene | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04725331 ↗ |
| Known as | TG6030 | “A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily...” NCT04725331 ↗ |
| Route | Other | “delivered by intra-tumoural injection” NCT07687875 ↗ |
| Target | CTLA4 | “Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF” NCT04725331 ↗ |